Table 4. Baseline characteristics: Randomized clinical trials versus the GARFIELD Registry.
| GARFIELD(Cohort 1) | RELY-AF [31] (dabigatran) | ROCKET AF [32] (rivaroxaban) | AVERROES [26] (apixaban) | ARISTOTLE (apixaban) [33] | ||||||
| (n = 10,614) | D 110(n = 6015) | D 150(n = 6076) | Warf(n = 6022) | Rivarox(n = 7131) | Warfarin(n = 7133) | Apixaban(n = 2808) | Aspirin(n = 2791) | Apixaban(n = 9120) | Warfarin(n = 9081) | |
| Age in years | 70±11 | 71±9 | 72±9 | 72±9 | 73 (65,78) | 73 (65,78) | 70±9 | 70±10 | 70 (63,76) | 70 (63,76) |
| Women | 43 | 36 | 37 | 37 | 40 | 40 | 41 | 42 | 36 | 35 |
| BMI (kg/m2) | 28±5 | – | – | – | 28 (25,32) | 28 (25,32) | 28±5 | 28±5 | – | – |
| Age ≥75 years | 39 | – | – | – | – | – | – | – | 31 | 31 |
| Prior stroke/TIA | 14 | 20 | 20 | 20 | – | – | 14 | 13 | – | – |
| Diabetes | 22 | 23 | 23 | 23 | 40 | 40 | 19 | 20 | 25 | 25 |
| Prior myocardial infarction | 10* | 17 | 17 | 16 | 17 | 18 | – | – | 15 | 14 |
| Hypertension | 78 | 79 | 79 | 79 | 90 | 91 | 86 | 87 | 87 | 88 |
| Heart failure | 21 | 32 | 32 | 32 | 63 | 62 | 40 | 38 | 36† | 35† |
| Classification of AF | ||||||||||
| Paroxysmal | 28 | 32 | 33 | 34 | 18 | 18 | 27 | 27 | 15 | 16 |
| Persistent | 18 | 32 | 31 | 32 | 81 | 81 | 21 | 21 | 85 | 84 |
| Permanent | 25 | 35 | 36 | 34 | – | – | 52 | 52 | ||
| Newly diagnosed or new onset | 30 | – | – | – | 1.4 | 1.4 | – | – | – | – |
| CHADS2 score | 1.9±1.2 | 2.1±1.1 | 2.2±1.2 | 2.1±1.1 | 3.5±0.9 | 3.5±1.0 | 2.0±1.1 | 2.1±1.1 | 2.1±1.1 | 2.1±1.1 |
Data given as %, mean±SD or median (IQR).
*
History of acute coronary syndrome.
†
Heart failure or reduced left ventricular ejection fraction.
AF, atrial fibrillation; BMI, body mass index; CHADS2, Cardiac failure, Hypertension, Age, Diabetes, Stroke (Doubled), COPD, chronic obstructive pulmonary disease; D, dabigatran; SD, standard deviation; TIA, transient ischaemic attack.